No headlines found.
QuidelOrtho to Report Second Quarter 2026 Financial Results
PRNewswire (Fri, 24-Jul 7:00 AM ET)
Beyond Fentanyl: How the Drug Crisis Is Changing
PRNewswire (Thu, 23-Jul 9:21 AM ET)
Business Wire (Thu, 23-Jul 7:00 AM ET)
QuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PRNewswire (Wed, 15-Jul 7:32 PM ET)
QuidelOrtho Appoints Micah Young as Chief Financial Officer
PRNewswire (Tue, 23-Jun 7:12 AM ET)
PRNewswire (Tue, 2-Jun 7:12 AM ET)
When Blood Compatibility Becomes a Pregnancy Risk
PRNewswire (Thu, 21-May 9:18 AM ET)
QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences
PRNewswire (Wed, 20-May 7:00 AM ET)
QuidelOrtho Reports First Quarter 2026 Financial Results
PRNewswire (Tue, 5-May 4:05 PM ET)
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
Quidelortho trades on the NASDAQ stock market under the symbol QDEL.
As of July 28, 2026, QDEL stock price climbed to $16.99 with 371,788 million shares trading.
QDEL has a beta of 2.06, meaning it tends to be more sensitive to market movements. QDEL has a correlation of 0.10 to the broad based SPY ETF.
QDEL has a market cap of $1.16 billion. This is considered a Small Cap stock.
Last quarter Quidelortho reported $620 million in Revenue and -$.04 earnings per share. This fell short of revenue expectation by $-31 million and missed earnings estimates by -$.45.
In the last 3 years, QDEL traded as high as $88.14 and as low as $9.92.
The top ETF exchange traded funds that QDEL belongs to (by Net Assets): IJR, AVUV, VTI, IWM, VB.
QDEL has underperformed the market in the last year with a price return of -38.0% while the SPY ETF gained +17.7%. However, in the short term, QDEL had mixed performance relative to the market. It has outperformed in the last 3 months, returning +38.2% vs +4.1% return in SPY. But in the last 2 weeks, QDEL shares have been beat by the market, returning -5.0% compared to an SPY return of -0.9%.
QDEL support price is $16.02 and resistance is $17.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QDEL shares will trade within this expected range on the day.